Evidence map›Paper›PMID 36495390›Full record

ArticleEndocrine2023

Alessio Rizzo, Manuela Racca, Simona Cauda, Michele Balma, Sara Dall'Armellina, Beatrice Dionisi, Claudio Mossetti, Maria Cristina Bruna, Milena Freddi, Nicola Palestini

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The Diagnostic Accuracy of [Diagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Expanding the clinical indications of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  4. The role ofGland surgery · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alessio RizzoCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy. alessio.rizzo@ircc.it.
Manuela RaccaCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Simona CaudaCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Michele BalmaNuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy.
Sara Dall'ArmellinaNuclear Medicine Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.
Beatrice DionisiCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Claudio MossettiCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Maria Cristina BrunaCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Milena FreddiCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Nicola PalestiniCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis retrospective study aims to establish

methodsForty patients with suspect primary hyperparathyroidism (pHPT) and negative/equivocal conventional imaging underwent FCH-PET/CT in our Institution. For every lesion, visual and semi-quantitative analyses were performed on PET/CT images. In qualitative analysis, a lesion was considered positive if a clear focus of uptake, significantly higher than normal thyroid tissue, was identifiable. Ectopic focal uptake was also regarded as positive PET result. Lesion SUV

resultsFour out of the 40 patients who underwent surgery for pHPT had more than one histologic proven unhealthy parathyroid and three had papillary thyroid cancer (PTC). A total of 48 lesions were analyzed. We found 42/48 lesions (87.5%) to have true-positive uptake, whereas three lesions (6.7%) had false-positive uptake (PTC). Three histologic proven parathyroid adenomas showed no uptake (6.7%); the sensitivity/PPV were 93.3% and accuracy was 87,8%. Pearson's test showed a significant correlation between PTH values and parathyroid size with SUVr values (r = 0.56 and 0.55, respectively, p < 0.01 for both features). DISCUSSION: As stated in recent literature, we observed excellent diagnostic sensitivity of FCH-PET/CT in patients with pHPT, providing surgeons a fine tool to optimize treatment. More studies are needed to improve the evaluability of semi-quantitative parameters towards a further improvement of diagnostic accuracy.

Indexed as

Hyperparathyroidism, PrimaryPositron Emission Tomography Computed TomographyCholineHumansParathyroid GlandsRetrospective StudiesCholinefluorocholinefluoromethylcholine18F-FluocholinePET/CTPrimary hyperparathyroidismSemi-quantitative analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.